Johnson & Johnson (NYSE:JNJ) Shares Acquired by EP Wealth Advisors LLC

EP Wealth Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 352,419 shares of the company’s stock after purchasing an additional 9,578 shares during the period. Johnson & Johnson makes up approximately 1.4% of EP Wealth Advisors LLC’s portfolio, making the stock its 9th biggest holding. EP Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $62,558,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. RE Dickinson Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC boosted its stake in shares of Johnson & Johnson by 200.0% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares during the last quarter. Morton Brown Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares during the last quarter. Professional Financial Advisors LLC boosted its stake in shares of Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $39,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

Johnson & Johnson stock opened at $177.01 on Thursday. The stock has a market cap of $462.79 billion, a P/E ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The firm’s fifty day moving average price is $168.35 and its 200-day moving average price is $171.28. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.60 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has initiated a stock repurchase plan on Wednesday, September 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a yield of 2.55%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling

In related news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares in the company, valued at $18,864,202. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares in the company, valued at $18,864,202. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider William Hait sold 15,000 shares of the company’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 212,646 shares of company stock worth $36,791,022. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on JNJ shares. Raymond James lowered their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Barclays started coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target on the stock. Bank of America lowered their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Finally, Credit Suisse Group began coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price on the stock. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.33.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.